Paul Mark B. Medina

This paper shows that truncating ASXL1 variants disrupt mitochondrial pyruvate transport, leading to metabolic changes and Wnt signaling dysregulation in Bohring-Opitz syndrome and myeloid leukemia.

This paper shows that MRTX1133, a non-covalent KRAS (G12D) inhibitor, also inhibits KRAS (G12C) with high affinity and suppresses MAPK signaling in pancreatic cancer cells but not lung cancer cells.